Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 18Cholangiocarcinoma 3Thyroid Neoplasms 2Recurrence 1Neoplasms, Glandular and Epithelial 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Coitus 1Carcinoma, Renal Cell 1Carcinoma 1Biliary Tract Neoplasms 1

Interventions

temsirolimus 2Sunitinib 2Sorafenib 2Axitinib 2sonidegib 1niraparib 1lenvatinib 1gadolinium ethoxybenzyl DTPA 1donafenib 1Transurethral Resection of Prostate 1Therapeutics 1Phlebotomy 1Palliative Care 1Mitomycin 1Methylation 1Maintenance 1Interviews as Topic 1Hyperthermic Intraperitoneal Chemotherapy 1HhAntag691 1Hepatectomy 1Fatty Acids, Omega-6 1Endoscopy 1Cetuximab 1Breath Tests 1Blood Specimen Collection 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Carcinoma × lenvatinib × Clear all
NCT04008082 2022-03-08

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Eisai Inc.

Completed
412 enrolled
Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡